Functional disability and its predictors in systemic sclerosis: A study from the DeSScipher project within the EUSTAR group

Rheumatology (United Kingdom)

Volumn 57, Issue 3, 2018, Pages 441-450

  Jaeger, Veronika K ^a   Distler, Oliver ^b   Maurer, Britta ^b   Czirják, Laszlo ^c   Lóránd, Veronika ^c   Valentini, Gabriele ^d   Vettori, Serena ^d   Del Galdo, Francesco ^e   Abignano, Giuseppina ^e   Denton, Christopher ^f   Nihtyanova, Svetlana ^f   Allanore, Yannick ^g   Avouac, Jerome ^g   Riemekasten, Gabriele ^h   Siegert, Elise ⁱ   Huscher, Dörte ^j   Matucci Cerinic, Marco ^k   Guiducci, Serena ^k   Frerix, Marc ^l   Tarner, Ingo H ^l   Toth, Beata Garay ^m   Fankhauser, Beat ⁿ   Umbricht, Jörg ⁿ   Zakharova, Anastasia ^o   Mihai, Carina ^p   Cozzi, Franco ^q   Yavuz, Sule ^r   Hunzelmann, Nicolas ^s   Rednic, Simona ^t   Vacca, Alessandra ^u   Schmeiser, Tim ^v   Riccieri, Valeria ^w   De la Peña Lefebvre, Paloma García ^x   Gabrielli, Armando ^y   Krummel Lorenz, Brigitte ^z   Martinovic, Duska ^aa   Ancuta, Codrina ^ab   Smith, Vanessa ^ac   Müller Ladner, Ulf ^l   Walker, Ulrich A ^a   more..

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF PÉCS   (Hungary)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

^e UNIVERSITY OF LEEDS   (United Kingdom)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

ⁱ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^j German Rheumatism Research Centre   (Germany)

^k UNIVERSITY OF FLORENCE   (Italy)

^l JUSTUS LIEBIG UNIVERSITY   (Germany)

^m Federation European Scleroderma Associations (FESCA)   (Hungary)

ⁿ New win SW Solutions AG ^*  (Switzerland)

^o V A NASONOVA RESEARCH INSTITUTE OF RHEUMATOLOGY   (Russian Federation)

^p CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^q UNIVERSITY OF PADOVA   (Italy)

^r MARMARA UNIVERSITY   (Turkey)

^s UNIVERSITY OF COLOGNE   (Germany)

^t IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^u UNIVERSITY OF CAGLIARI   (Italy)

^v Krankenhaus St Josef   (Germany)

^w SAPIENZA UNIVERSITY OF ROME   (Italy)

^x Hospital Universitario Madrid Norte Sanchinarro   (Spain)

^y UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^z Endokrinologikum Frankfurt   (Germany)

^aa UNIVERSITY HOSPITAL SPLIT   (Croatia)

^ab GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^ac GHENT UNIVERSITY   (Belgium)

more..

Author keywords

Functional disability; Predictors of disability; Scleroderma health assessment questionnaire; Systemic sclerosis

Indexed keywords

CARBON MONOXIDE;

ADULT; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; DIASTOLIC DYSFUNCTION; DISABILITY; DISEASE SEVERITY; DYSPNEA; ESOPHAGUS; FEMALE; FINGER ULCER; FORCED VITAL CAPACITY; FUNCTIONAL STATUS; GASTROINTESTINAL SYMPTOM; HEALTH ASSESSMENT QUESTIONNAIRE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INTESTINE; JOINT CONTRACTURE; LUNG ARTERY PRESSURE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUSCLE ATROPHY; MUSCLE WEAKNESS; NERVE BLOCK; NEW YORK HEART ASSOCIATION CLASS; PERICARDIAL EFFUSION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCLERODERMA HEALTH ASSESSMENT QUESTIONNAIRE; STOMACH; SYNOVITIS; SYSTEMIC SCLEROSIS; TELANGIECTASIA; VISUAL ANALOG SCALE; CLINICAL TRIAL; COMPLICATION; DAILY LIFE ACTIVITY; EUROPE; GASTROINTESTINAL DISEASE; LONGITUDINAL STUDY; MULTICENTER STUDY; PAIN MEASUREMENT; PATHOPHYSIOLOGY; PSYCHOLOGY; PULMONARY HYPERTENSION; QUALITY OF LIFE; REGRESSION ANALYSIS; RISK FACTOR; SEVERITY OF ILLNESS INDEX; SICKNESS IMPACT PROFILE; SKIN ULCER;

ACTIVITIES OF DAILY LIVING; DISABILITY EVALUATION; EUROPE; GASTROINTESTINAL DISEASES; HUMANS; HYPERTENSION, PULMONARY; LONGITUDINAL STUDIES; MUSCLE WEAKNESS; PAIN MEASUREMENT; PROSPECTIVE STUDIES; QUALITY OF LIFE; REGRESSION ANALYSIS; RISK FACTORS; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; SICKNESS IMPACT PROFILE; SKIN ULCER;

EID: 85043311396     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kex182     Document Type: Article

References (39)

1. Hudson M, Thombs BD, Steele R et al. Health-related quality of life in systemic sclerosis: a systematic review. Arthritis Rheum 2009;61:1112-20.
2. Johnson SR, Glaman DD, Schentag CT, Lee P. Quality of life and functional status in systemic sclerosis compared to other rheumatic diseases. J Rheumatol 2006;33:1117-22.
3. Mouthon L, Mestre-Stanislas C, Berezne A et al. Impact of digital ulcers on disability and health-related quality of life in systemic sclerosis. Ann Rheum Dis 2010;69:214-7.
4. Kwakkenbos L, Jewett LR, Baron M et al. The Scleroderma Patient-centered Intervention Network (SPIN) Cohort: protocol for a cohort multiple randomised controlled trial (cmRCT) design to support trials of psychosocial and rehabilitation interventions in a rare disease context. BMJ Open 2013;3:e003563.
5. Suarez-Almazor ME, Kallen MA, Roundtree AK, Mayes M. Disease and symptom burden in systemic sclerosis: a patient perspective. J Rheumatol 2007;34:1718-26.
6. Steen VD, Medsger TA. The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 1997;40:1984-91.
7. Johnson SR, Hawker GA, Davis AM. The health assessment questionnaire disability index and scleroderma health assessment questionnaire in scleroderma trials: an evaluation of their measurement properties. Arthritis Rheum 2005;53:256-62.
8. Pope J. Measures of systemic sclerosis (scleroderma):Health Assessment Questionnaire (HAQ) and Scleroderma HAQ (SHAQ), Physician- and Patient-Rated Global Assessments, Symptom Burden Index (SBI), University of California, Los Angeles, Scleroderma Clinical Trials Consortium Gastrointestinal Scale (UCLA SCTC GIT) 2.0, Baseline Dyspnea Index (BDI) and Transition Dyspnea Index (TDI) (Mahler's Index), Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR), and Raynaud's Condition Score (RCS). Arthritis Care Res 2011;63(Suppl 1):S98-S111.
9. Bruce B, Fries JF. The Health Assessment Questionnaire (HAQ). Clin Exp Rheumatol 2005;23(5 Suppl 39):S14-8.
10. Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation. J Rheumatol 2003;30:167-78.
11. Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: dimensions and practical applications. Health Qual Life Outcomes 2003;1:20.
12. Merkel PA, Herlyn K, Martin RW et al. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum 2002;46:2410-20.
13. Smyth AE, MacGregor AJ, Mukerjee D et al. A crosssectional comparison of three self-reported functional indices in scleroderma. Rheumatology 2003;42:732-8.
14. Racine M, Hudson M, Baron M, Nielson WR. The impact of pain and itch on functioning and health-related quality of life in systemic sclerosis: an exploratory study. J Pain Symptom Manage 2016;52:43-53.
15. Franck-Larsson K, Graf W, Rönnblom A. Lower gastrointestinal symptoms and quality of life in patients with systemic sclerosis: a population-based study. Eur J Gastroenterol Hepatol 2009;21:176-82.
16. Omair MA, Lee P. Effect of gastrointestinal manifestations on quality of life in 87 consecutive patients with systemic sclerosis. J Rheumatol 2012;39:992-6.
17. Hughes M, Snapir A, Wilkinson J et al. Prediction and impact of attacks of Raynaud's phenomenon, as judged by patient perception. Rheumatology 2015;54:1443-7.
18. Strickland G, Pauling J, Cavill C, McHugh N. Predictors of health-related quality of life and fatigue in systemic sclerosis:evaluation of the EuroQol-5D and FACIT-F assessment tools. Clin Rheumatol 2012;31:1215-22.
19. Chow S, Pope JE, Mehta S. Lack of correlation of the health assessment questionnaire disability index with lung parameters in systemic sclerosis associated pulmonary arterial hypertension. Clin Exp Rheumatol 2008;26:1012-7.
20. Lumetti F, Barone L, Alfieri C et al. Quality of life and functional disability in patients with interstitial lung disease related to Systemic Sclerosis. Acta Biomed 2015;86:142-8.
21. Guillevin L, Hunsche E, Denton CP et al. Functional impairment of systemic scleroderma patients with digital ulcerations:results from the DUO Registry. Clin Exp Rheumatol 2013;31(2 Suppl 76):71-80.
22. Frantz C, Avouac J, Distler O et al. Impaired quality of life in systemic sclerosis and patient perception of the disease:a large international survey. Semin Arthritis Rheum 2016;46:115-23.
23. Frerix M, Abignano G, Allanore Y et al. SAT0467 The Five Prospective Observational Trials of the International Systemic Sclerosis FP7-Health Research Project Desscipher: A Interim Report. Ann Rheum Dis 2015;74(Suppl 2):829.3-30.
24. The DeSScipher Project. https://www.uni-giessen.de/fbz/ fb11/institute/klinik/rheumatologie/desscipher-en (9 November 2015, date last accessed).
25. Walker UA, Tyndall A, Czirják L et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007;66:754-63.
26. Meier FMP, Frommer KW, Dinser R et al. Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 2012;71:1355-60.
27. van den Hoogen F, Khanna D, Fransen J et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2013;65:2737-47.
28. Masi AT, Rodnan GP, Medsger TA Jr et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
29. Georges C, Chassany O, Mouthon L et al. Validation of French version of the Scleroderma Health Assessment Questionnaire (SSc HAQ). Clin Rheumatol 2005;24:3-10.
30. Sterne J, White IR, Carlin JB et al. Multiple imputation for missing data in epidemiological and clinical research:potential and pitfalls. BMJ 2009;338:b2393.
31. Carpenter JR, Kenward MG. Multiple Imputation and its Application, 1st edn. Chichester: John Wiley & Sons, 2013.
32. Wells GA, Tugwell P, Kraag GR et al. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993;20:557-60.
33. Dworkin RH, Turk DC, Wyrwich KW et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008;9:105-21.
34. Strand V, Smolen JS, van Vollenhoven RF et al. Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial. Ann Rheum Dis 2011;70:996-1002.
35. Brand M, Hollaender R, Rosenberg D et al. An observational cohort study of patients with newly diagnosed digital ulcer disease secondary to systemic sclerosis registered in the EUSTAR database. Clin Exp Rheumatol 2015;33(4 Suppl 91):S47-54.
36. Lóránd V, Czirják L, Minier T. Musculoskeletal involvement in systemic sclerosis. Presse Med 2014;43:e315-28.
37. Bassel M, Hudson M, Taillefer SS et al. Frequency and impact of symptoms experienced by patients with systemic sclerosis: results from a Canadian National Survey. Rheumatology 2011;50:762-7.
38. Loos-Ayav C, Chau N, Riani C, Guillemin F. Functional disability in France and its relationship with health-related quality of life _ a population-based prevalence study. Clin Exp Rheumatol 2007;25:701-8.
39. Oude Voshaar MAH, ten Klooster PM, Taal E et al. Linking physical function outcomes in rheumatology:Performance of a Crosswalk for Converting Health Assessment Questionnaire Scores to Short Form 36 Physical Functioning Scale Scores. Arthritis Care Res 2014;66:1754-8.